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Abstract 
Introduction: The development of improved cancer therapies is frequently cited as 
an urgent unmet medical need. Here we review how recent advances in platform 
technologies and the increasing availability of biological ‘big data’ are providing an 
unparalleled opportunity to systematically identify the key genes and pathways 
involved in tumorigenesis. We then discuss how these discoveries may be amenable 
to therapeutic interventions. 
Areas covered: We discuss the current approaches that use ‘big data’ to identify 
cancer drivers. These approaches include genomic sequencing, pathway data, multi-
platform data, identifying genetic interactions such as synthetic lethality and using 
cell line data. We review how big data is being used to assess the tractability of 
potential drug targets and how systems biology is being utilised to identify novel drug 
targets. We finish the review with an overview of available data repositories and tools 
being used at the forefront of cancer drug discovery. 
Expert opinion: Targeted therapies based on the genomic events driving the 
tumour will eventually inform treatment protocols. However, using a tailored 
approach to treat all tumour patients may require developing a large repertoire of 
targeted drugs. 
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1  Introduction 
Cancer represents a major and rising global health burden, with over 12 million 
newly diagnosed cases per annum, and is responsible for more than 15% of the 
world’s annual deaths. The development of new improved cancer therapies is 
frequently cited as an urgent unmet medical need [1]. 
Traditionally, cancer therapies were dominated by cytotoxic agents: These therapies 
cause damage to DNA that exceeds a cancer cell’s capacity to repair itself and have 
been the mainstay of cancer chemotherapy for over 30 years [2]. Although effective 
in treating cancers’ such as testicular and breast, as well as childhood leukaemias, 
these agents are relatively unsuccessful in the treatment of many cancers including 
lung, brain, pancreatic, and oesophageal tumours, even when used in combinations 
[3,4]. 
More recently in drug discovery, the focus has changed to identifying genomic and 
other molecular abnormalities in cancer subtypes with a view to develop targeted 
therapies that offer the possibility of greater efficacy and therapeutic selectivity [5]. 
Early successes of single agent targeted therapies looked very promising. Two key 
examples, trastuzumab [6] and imatinib [7] are used in the treatment of breast 
cancer and chronic myeloid leukaemia respectively. Trastuzumab is a monoclonal 
antibody that specifically targets cells that are over-expressing the human epidermal 
growth factor receptor HER2/ERBB2, whilst imatinib, a small molecule, directly 
inhibits constitutively activated Abl kinase caused by the BRC-ABL translocation. 
Whilst these some of these targeted therapies have been particularly effective it 
appears that they may be somewhat unusual as some of the newer targeted 
therapies have provided at best only short-lived remissions before resistance takes 
hold [8,9]. However recent advances in platform technologies have provided an 
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unparalleled opportunity to comprehensively identify the alterations, genes, and 
pathways involved in tumorigenesis, raising the expectation of extending targeted 
therapies [10,11]. 
Here we review the ‘big data’ approaches for identifying the driver genes in cancer 
and discuss the approaches used to determine which of these would be good drug 
targets. We also highlight some of the excellent online data resources available to 
the cancer drug discovery community. Furthermore we discuss some of the 
challenges faced by the large repositories that contain cancer and biological data 
and how these issues are being addressed by new developments such as 
ICGCmed. 
 
2 Cancer types and subtypes 
Historically, the ~200 cancer types (and sub-types) described were characterised by 
the shape and location of the tumour and its growth progression. Heterogeneous 
populations of tumours can now be clustered into clinically and biologically 
meaningful subtypes using similarity of molecular profiles (e.g. [12]). As a cancer 
evolves, it induces dynamic changes in the genome. These include somatic 
mutations, copy number variations, abnormal gene expression, and deleterious 
epigenetic patterns. The result of this is that each individual patient's cancer will be 
unique. However the pathways affected in different cancer types and subtypes of 
tumours are similar and as such the same therapeutic strategies can often be used 
for groups of patients. In addition, it is these genetic and phenotypic changes that 
occur during tumorigenesis that alter the set of genes upon which cells become 
dependent. These changes generate vulnerabilities that can often be translated into 
successful therapeutic approaches. 
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2.1 Identifying cancer drivers 
In the majority of cancers most of the genetic changes acquired as the disease 
progresses are inconsequential in terms of driving the cancer phenotype, however a 
few of the changes in a small set of genes are crucial to the development or the 
sustainability of the disease. The genes that harbour these critical alterations are 
called ‘driver genes’ and many studies powered by major international consortia 
have been undertaken to identify them (e.g. [13–16]). 
 
2.1.1 Sequencing approaches for identifying cancer drivers 
Initial studies using ‘big data’ approaches focused on identifying mutated driver 
genes in groups of patient samples. The Cancer Genome Project analysed 274 
megabases (Mb) of DNA, corresponding to the coding exons of 518 protein kinase 
genes in 210 diverse human cancers [17]. The study identified 1,000 somatic 
mutations and used a statistical approach to rank each of the kinases studied on the 
probability of it containing a driver mutation. Similarly Vogelstein and co-workers 
analysed the exons representing 20,857 transcripts from 18,191 genes in 11 
colorectal and 11 breast tumours. Genes mutated more frequently than would be 
predicted by chance were identified as likely drivers. They also described the first 
genomic landscapes of breast and colorectal cancers [18]. As technology has 
improved and the costs of sequencing reduced, many other studies have worked 
with both disease based and pan-cancer somatic mutational data to identify 
‘mutation’ driver genes (e.g. [19–21]). 
 
2.1.2 Multi-platform approaches for identifying cancer drivers 
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Due to the complexity of the changes in cancer, multi-platform approaches have also 
been developed. These use complementary high-throughput technologies to 
measure somatic mutations, as well as copy number variation (CNV), altered 
patterns of epigenetic modification, and changes in levels of transcription and protein 
expression. These large-scale studies have now surveyed ~30 individual tumour 
types with large cohorts of patients. Statistical approaches (e.g. [14,22]) can then be 
used to identify the significantly altered genes. These approaches have proven 
promising for identifying the highly recurrent altered genes that can provide novel 
drug targets (see figure 1). 
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Figure 1. This figure illustrates how large-scale multi-platform analysis of large 
cohorts of patients can be used to identify driver genes that are potential cancer drug 
targets. ‘Multiomics Data’ illustrates the types of data collected for each individual 
data. This includes; mutation data that maps somatic genetic muta- tions in human 
patients that can be used to highlight genes that are recurrently mutated in certain 
cancer subtypes. Copy number variation maps how sections of the genome, and 
potentially whole genes, are repeated. Gene expression data is used to estimate 
transcription RNA expression levels for each gene. DNA methylation data maps 
epigenetic markers. MicroRNA data maps non-coding RNA molecules that function 
in RNA. Protein expression data maps the levels of known proteins in each cell and 
clinical data provides important information about the patient and their outcome. 
Through modelling using tools such machine learning decision tree based classifiers 
or other statistical methods these datasets can be analysed together to identify driver 
genes that have the potential to be cancer drug targets.  
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Brennan and co-workers [13] described the landscape of somatic genomic 
alterations based on the genomic and proteomic profiles of more than 500 examples 
of glioblastoma (GBM). In addition to alterations in the signature oncogenes of GBM, 
such as EGFR and PI3K, they found that over 40% of tumours contained missense 
mutations among the chromatin-modifier genes. Pereira et al. [14] analysed the 
genomic and transcriptomic landscapes of breast cancers of 2,433 breast cancers 
found that PIK3CA and TP53 were the most frequently mutated genes with only five 
other genes harbouring coding mutations in at least 10% of the samples (AHNAK2, 
KMT2C, GATA3, MUC16, SYNE1). Giannakis et al. [15] performed whole-exome 
sequencing of 619 colorectal cancers and integrated the results with tumour 
immunity, pathology, and survival data identifying previously undetected recurrently 
mutated genes. 
Pickering et al. [23] identified a number of frequently mutated drivers in oral 
squamous cell carcinoma (OSCC) through the comprehensive genomic analysis of 
gene expression, methylation, copy number and point mutations. Zheng et al. [24] 
collected the clinical and pathologic features, genomic alterations, DNA-methylation 
profiles, and RNA and proteomic signatures of 91 cases of Adrenocortical 
Carcinoma identifying at least 6 driver genes including TP53, ZNFR3, CTNNB1, 
PRKAR1A, CCNE1, and TERF2. 
Several studies have surveyed multi-omic data from multiple tumour types to identify 
driver genes (e.g. [20,25]]). For example, working at a pan-cancer level Mo et al. [26] 
developed iCluster+. This method performs pattern discovery that integrates diverse 
data types including pan-cancer somatic mutation, copy number gain, normal, loss 
and gene expression values to predict driving factors in cancers. These multi-
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platform approaches are revealing a growing list of driver genes across the most 
common human cancers [16,27–29]. 
 
2.1.3 Actionable drivers 
Driver genes can be broadly classified by the manner in which, when altered, they 
contribute to the disease process. In oncogenes an increase in activity, a gain or, 
more rarely, a change of function (GOF) is required for tumorigenesis whereas 
tumour suppressors contribute to the development of cancer when genetic changes 
(or epigenetic silencing) result in a loss of function (LOF) . 
From a drug discovery perspective, targeting these two different types of drivers 
requires a very different approach. Oncogenic GOF drivers can often be targeted 
directly - for example dabrafenib has been approved for the treatment of late-stage 
melanoma, and targets the constitutively activated oncogene BRAF V600E. In lung 
cancer, the genetic alterations observed in EGFR (the epidermal growth factor 
receptor) and ALK (anaplastic lymphoma kinase) have also resulted in the 
development of targeted therapies. Both genes encode pharmacologically targetable 
tyrosine kinases involved in growth factor receptor signalling. Cetuximab, 
panitumumab, gefitinib and erlotinib are licensed inhibitors of the EGFR tyrosine 
kinase and crizotinib is an ALK inhibitor all of which are licensed for the treatment of 
lung cancer [30–33]. 
Tumour suppressors usually have to be targeted indirectly using approaches such as 
synthetic lethality, or by reactivation (see section 2.1.5). 
 
2.1.3.1 The 20:20 rule 
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The classification of known driver genes as either tumour suppressor or oncogene is 
often well documented in the literature, although when a new driver is identified via a 
high-throughput approach, its class can often be unclear. However, the mutational 
patterns observed in cohorts of tumour samples differ markedly between tumour 
suppressor and oncogenes and several groups have used data from whole exome 
sequencing of large data sets to automatically distinguish between them on that 
basis [34–36]. 
Vogelstein's ‘20:20 rule’ [16] asserts that if 20% of all mutations observed in a gene 
within a cohort of tumour samples are truncations, then that gene is likely to be a 
tumour suppressor, whereas if 20% of all missense mutations occur at a single 
position in the sequence, the gene is predicted to be an oncogene [37].  
 
 
2.1.4 Pathway approaches for identifying actionable drivers 
Even with the large quantities of patient data currently available there is not always 
the statistical power available to identify driver genes that occur with low frequency. 
Many genes within a biological pathway may contribute to tumour biology even 
though they are only infrequently altered. Systematic mapping of these low 
frequency drivers can highlight key pathways that offer ‘druggable’ targets for novel 
therapeutic strategies. 
The most straightforward approach to identifying target pathways from infrequent 
events, is through fixed-gene set enrichment analysis. In this approach fixed gene 
sets are constructed based on known biological pathways and processes. It is then 
possible to assess whether there are more gene disruption events within the set than 
expected by chance (e.g. [38–43]). Known pathways can also be extended with 
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pathways based on genes that are predicted to have similar functionality, using tools 
such as GeneMania [44]. Similarly, local network properties can be used to predict 
which related proteins are affected and these smoothed networks are then clustered 
[45]. 
 
2.1.5 Synthetic lethality approaches 
Driver tumour suppressors pose a particular challenge in drug discovery. 
Occasionally, it may be possible to directly re-activate a mutationally inactivated 
tumour suppressor. Post-translational re-activation of a protein requires that the 
inactivating mutation does not truncate or ablate the protein product but generates a 
form amenable to stabilisation by a modifying ligand. This approach is being 
explored for a subset of destabilising mutations of TP53 (reviewed in [46]). 
The alternative strategy for targeting LOF of tumour suppressors is the identification 
of other ‘complementary’ gene products that will be the actual pharmacological target 
using the concept of synthetic lethality. Synthetic lethal (SSL) interactions describe 
the situation where either gene in a pair of genes can be disrupted without 
significantly affecting cell viability, whilst disruptions in both genes causes cell death 
[47]. Synthetic sensitivity results in impaired cell growth or proliferation, which may 
lead to cell death in the presence of additional stresses or additional therapeutic 
insults. In practice, therapeutic SSL responses are likely to be on a spectrum, with 
the ideal being single-agent lethality. 
To exploit SSL therapeutically, the genetic defects in an affected pathway must be 
combined with a pharmacologically induced defect in a compensating pathway [48], 
an approach that may provide significantly improved therapeutic indices compared to 
standard chemotherapies [49]. 
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Genes involved in DNA damage response (DDR) are prime candidates for SSL 
interactions as there are multiple complementary pathways for repairing DNA and 
many of the DDR genes exhibit LOF defects in a variety of tumours [2,50]. The best 
current example of therapeutic exploitation of SSL is the inhibition of PARP1 [51] a 
key enzyme in single strand break repair which is SSL with genetic defects in the 
BRCA1, BRCA2 or PALB2 homologous recombination (HR) proteins commonly 
observed in hereditary breast, ovarian, prostate and pancreatic cancers (Figure 2). 
 
 
Figure 2:  An illustration of the therapeutic value of synthetic lethality approaches for 
targeting cancer cells. When DNA is damaged in a healthy cell, it can be repaired by 
several mechanisms including single strand break repair (SSBR) and homologous 
recombination (HR). In tumour cells where BRCA1 or BRCA2 is genetically 
inactivated by mutation, the DNA in the cell can no longer be repaired by HR, 
however the cells are still viable as SSBR is still working.  In healthy cells, where 
PARP is inactivated by targeted inhibitors, the DNA can no longer be repaired by 
SSBR, but the cells are still viable as HR still occurs.  In tumour cells where BCRA1 
or BRCA2 are genetically inactivated, and the PARP genes inactivated by PARP 
inhibitors damaged, DNA cannot be efficiently repaired.  This leads to the 
accumulation of genetic damage in the cell and ultimately to cell death. 
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Historically a ‘hypothesis driven’ process, the prediction of SSL interactions has 
traditionally been based on proven associations, often related to loss of particular 
cell cycle checkpoints or pathways related to those of known tumour suppressors or 
by homology in model organisms [52,53]. This approach has worked well to identify 
a small numbers of SSL interactions but the experimental burden of screening many 
pairwise candidates had prohibited any large scale systematic studies of human 
synthetic lethality. The increased availability of genetically modified human cell lines 
and high throughput genetic screening combining RNAi screens with libraries of 
chemical inhibitors has allowed the search to widen [54] and a number of statistical, 
probabilistic and machine learning models have proved both cheaper and faster to 
implement compared to traditional screening methods and have demonstrated 
impressive levels of accuracy when predicting SSL interactions [55]. These studies 
have approached the prediction of SSL interactions in diverse ways - including 
DAISY which utilises somatic copy number and mutation profiles [56] as well as 
studies that focus on RNAseq data [57], phosphorylation levels between signalling 
pathways [58], gene ontology, co-expression data and protein interaction data [59]. 
Biological networks have also been a focus of study [60–62] with genome-wide 
protein interaction network parameter data across species being used to predict 
genetic interactions [63,64]. A number of collated and curated SSL interactions for 
humans and model organisms are available via BioGRID [59]. 
 
2.1.6 Synthetic dosage lethality (SDL) 
The protein products of several potent oncogenes such as MYC and KRAS lack 
drug-like binding ‘pockets’ in their protein structure [65] and as a result they are 
mostly unamenable to current small-molecule drug discovery approaches. Big data 
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approaches to produce therapies for these ‘undruggable’ oncogenes include high 
throughput screening to find their synthetic dosage lethality partners. Similar to SSL, 
SDL causes cell death as a result of one gene being genetically activated (GOF, the 
oncogene) and another being inactivated (LOF, the drug target). 
Several groups have utilised screening approaches to identify the SDL partners of 
activated mutant KRAS, which is frequently observed in subsets of lung and 
colorectal cancers [66]. A genome-wide shRNA screen in colorectal cancer cells and 
found that KRAS mutants were hypersensitive to APC/C and PLK1, whereas SDL 
partners that have been identified through RNAi screening include CDK1, CDK4, 
GATA2, Snail2, STK33, TBK1 and WT1 [67–72]. 
 
2.1.7 Non-oncogene addiction 
The viability of a cancer cell is dependent on a variety of genes and pathways that 
are not inherently oncogenic themselves [37] but are essential to support the 
phenotype of cancer cells. This dependence - termed non-oncogene addiction - has 
been successfully targeted therapeutically. Examples in the clinic that use this 
approach include the hormone-recognition- and hormone-biosynthesis-targeting 
agents such as aromatase inhibitors for breast cancer and the cytochrome P450 
family 17 subfamily A member 1 (CYP17A1) inhibitors for prostate cancer [29]. 
Where as those in the discovery phase include MTH1 which is essential in cancer 
cells as it cleanses oxidized dNTP pools to prevent incorporation of damaged bases 
during DNA replication [73,74]. 
One ‘big data’ approach to identifying cancer-specific vulnerabilities, including non-
oncogenic addiction therapeutic targets, is to profile genetic dependencies in cancer 
cell lines. Campbell et al. [75] completed a large scale siRNA screening of kinase 
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dependencies in 117 cancer cell lines from ten cancer types. By integrating the 
siRNA screen data with molecular profiling data, including exome sequencing data, 
they demonstrated that genetic dependencies associated with specific cancer driver 
gene mutations could be identified. Furthermore, by identifying dependencies that 
were present within the known functional relationships of driver genes or kinases, 
they were able to predict successfully that osteosarcoma cells would be sensitive to 
FGFR inhibitors and SMAD4 mutant tumour cells would be sensitive to mitotic 
inhibitors. 
 
2.2 Clinical trial design 
As well as potentially guiding the development of therapeutics an understanding of 
cancer subtypes can also help provide better frameworks for clinical trial design 
through the stratification of patient selection. Targeted therapies are often only 
effective for a sub-population of patients with the specific disease, for example, 
whilst there may be a large number of breast cancer patients, the subset with a 
specific genetic mutation driving that cancer, for example a BRCA1 mutation, may be 
much smaller. Without factoring these disease subtypes into a trial design the 
efficacy rate may suffer as a result. 
This notion of patient stratification has led to the development of a number of new 
trial frameworks such as ‘umbrella’ and ‘basket’ trials 
An umbrella trial tests multiple targeted therapies based on the disease subtype. 
During an umbrella test a number of patients with a specific disease will be stratified 
based on individual mutations and assigned to different arms of the trial each of 
which distributes therapy specific to that disease subtype [76]. Basket trials on the 
other hand focus on patients with a common mutation but with varied diseases, a 
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BRAF mutation for example is common in a number of diseases. In a basket trial all 
patients will be given a the same drug that targets the shared mutation [77,78]. 
These trial designs provide a platform for testing several therapies concurrently for a 
single disease or a range of diseases with a single therapy, effectively allowing us to 
run a number of trials at once improving both efficiency as well as efficacy rates 
through patient stratification [79]. 
 
3 Target tractability 
In combination, large-scale studies have uncovered extensive catalogues of genes 
whose protein products require assessment of their potential as viable drug targets 
or their ‘druggablity’ [28]. The druggability of a protein refers to whether the protein 
has the ability to bind small drug-like molecules with high affinity, this largely is 
dependent on its three dimensional structure 
Introduced in 2002, the concept of the ‘druggable genome’ identified the genes 
within the human genome that coded for proteins that could be modulated by small 
drug-like proteins [80]. A recent update has mapped 1,578 FDA-approved drugs act 
onto 893 human drug targets [29]. The original analysis evaluated the ‘druggability’ 
of all human proteins by calculating their sequence identity to known therapeutic 
targets and predicted that over 10% of the human proteome was druggable. More 
recently methods have expanded this number of druggable proteins. Methods been 
developed to predict druggability on proteins whose family members have previously 
been untargeted analysing of the protein’s 3D structure using machine learning 
based techniques [81–83]. Several studies have identified potential cancer drug 
targets from previously untargeted families using these types of approaches [2,84]. 
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4 Cancer Data Repositories and online analysis tools 
Much of the data produced from these large-scale studies have been produced by 
multi-national consortia and are available for independent analyses in large 
repositories or to browse using online tools. Here we highlight several key resources 
(see Table 1). 
COSMIC [66], the Catalogue Of Somatic Mutations In Cancer, focuses on curating 
and cataloguing all known somatic mutations in human cancer. It currently describes 
over 4 million coding mutations from over 1.25 million tumour samples. It includes 
data from 24,000 published studies as well as data from 29000 whole genome 
samples. The data is manually curated, allowing very precise definitions of disease 
types and patient details. 
The MOKCa database [85] has been developed to help researchers identify which 
genes are tumour suppressors, oncogenes and cancer drug targets and to highlight 
the driver mutations within them. Mutation data from the COSMIC database have 
been mapped to their protein products, and the mutations have been structurally and 
functionally annotated. 
The Genomic Data Commons (GDC) [86], which already holds 4.1 petabytes of data, 
provides curated storage for over 14,530 cancer cases, including those that were 
previously curated by the The Cancer Genome Atlas (TCGA) [87,88]. The repository 
includes clinical and biospecimen data, and provides access to multiple ‘omic’ data 
types such as mRNA expression, somatic mutations, copy number variation and 
protein abundance. Although the GDC is of fundamental importance to researchers, 
at the time of writing, the transition from TCGA to GDC has not been entirely smooth: 
methylation data has been archived rather than brought within the GDC hub and 
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some data on somatic nucleotide variations as well as TCGA explanatory information 
is not currently available. 
The International Cancer Genome Consortium (ICGC) [89] was established to 
coordinate large numbers of international research projects to identify the genomic 
changes present in a diverse range of cancers. Release 23 contains multi-platform 
data (somatic mutations, abnormal expression of genes, epigenetic modifications) 
from more than 16,000 cancer donors spanning 70 projects and 21 tumour sites. The 
aim of the ICGC is to make these data rapidly available to the research community, 
with minimal restrictions on the use of the data. ICGCmed is the next phase of the 
project and will link the current (and new) multi-platform data to clinical and health  
 
Resource 
name 
Description Reference URL 
Cosmic A catalogue of somatic 
mutations in cancer 
describing over 4 
million coding 
mutations from over 
1.25 million tumour 
samples. 
 [66] cancer.sanger.ac.uk/cosmic 
MOKCa MOKCa identifies 
tumour suppressors, 
oncogenes and cancer 
drug targets and 
highlights the driver 
mutations within them. 
 [85] strubiol.icr.ac.uk/extra/mokca 
Genomic 
Data 
GDC includes clinical 
and biospecimen data, 
 [86] gdc.cancer.gov 
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Commons 
(GDC) 
sequencing data for 
DNA, mRNA, and 
miRNA, and data on 
variants and mutations 
expression for genes, 
exons, and miRNA. 
The Cancer 
Genome Atlas 
(TCGA) 
An original source of 
much of GDC’s data 
TCGA provides similar 
data. 
 [87] cancergenome.nih.gov 
The 
International 
Cancer 
Genome 
Consortium 
(ICGC) 
The ICGC coordinates 
large numbers of 
international research 
projects to identify the 
genomic changes 
present in a diverse 
range of cancers. 
 [89] icgc.org 
cBioPortal cBioPortal allow 
researchers to perform 
integrated analysis of 
genetic, epigenetic, 
gene expression, and 
proteomic cancer data 
along with clinical 
profiles. 
 [38] www.cbioportal.org 
ChEMBL   ChEMBL is a large-
scale bioactivity 
database containing 
information manually 
extracted from the 
 [92] www.ebi.ac.uk/chembl 
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medicinal chemistry 
literature. 
The Cancer 
Cell Line 
Encyclopedia 
(CCLE) 
The CCLE contains 
pharmacological 
profiles for 24 
anticancer drugs 
tested across 479 
cancer cell lines. 
 [93] portals.broadinstitute.org/ccle/home 
The 
Genomics of 
Drug 
Sensitivity in 
Cancer 
(GDSC) 
The GDSC contains 
data from over 75,000 
experiments, 
describing the 
response to 138 
anticancer drugs 
across almost 700 
cancer cell lines. 
 [94] www.cancerrxgene.org 
NONCODE NONCODE features 
non-coding RNA 
details and sequences 
for non-coding RNA in 
16 species. 
 [95] www.noncode.org 
lncRNAdb   lncRNAdb provides 
non-coding RNA data 
including nucleotide 
sequences, genomic 
context, expression 
data, structural 
information, 
subcellular 
localisation, 
 [96] www.lncrnadb.org 
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conservation and 
functional annotation. 
 
Table 1: Description and URL of the resources discussed in the text 
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information. The intention is that this should include data on lifestyle, patient history, 
cancer diagnosis, and response to and survival following therapies. The quality of 
clinical information included within current ICGC data is variable at best. ICGCmed 
has the potential to be game-changing in the fight against cancer, but to achieve its 
aims it will be important to ensure that the quality control imposed on ‘omic’ data is 
extended to clinical data. 
Tools such as cBioPortal [38] allow researchers to perform integrated analysis of 
genetic, epigenetic, gene expression, and proteomic cancer data along with clinical 
profiles through an online platform for small subsets of genes (<30) [90]. It currently 
contains data from 147 cancer studies [38,91]. 
Although not containing cancer data per se, ChEMBL [92] is also a useful resource 
for cancer drug discovery. It is a large-scale bioactivity database containing 
information manually extracted from the medicinal chemistry literature. It contains 
information on proteins and the compounds tested against them (including their 
structures). It contains information on the biological and physicochemical assays 
performed on these targets, recorded in a structured form. 
The Cancer Cell Line Encyclopedia (CCLE) [93] profiles genetic dependencies in 
cancer cell lines. It contains pharmacological profiles for 24 anticancer drugs tested 
across 479 cancer cell lines that have been characterised by gene expression, 
chromosomal copy number and sequencing data. Analysis of these data has allowed 
identification of genetic, lineage, and gene-expression-based predictors of drug 
sensitivity. 
The Genomics of Drug Sensitivity in Cancer (GDSC) [94] database contains data 
from over 75,000 experiments, describing the response to 138 anticancer drugs 
across almost 700 cancer cell lines. Data includes somatic mutations, gene 
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amplification and deletion, tissue type and transcriptional data and is integrated with 
the cell line drug sensitivity data to provide molecular markers of drug response. 
Other Databases focus on non-coding genetic material such as non-coding 
functional RNA, for example, NONCODE [95] which features non-coding RNA details 
and sequences for non-coding RNA in 16 species including humans and lncRNAdb 
[96] which features details on non-coding RNA including nucleotide sequences, 
genomic context, expression data, structural information, subcellular localisation, 
conservation and functional annotation with referenced literature. 
 
 
5 Big data 
The growth of ‘big data’ in cancer research has been intensified by the advancement 
of technologies such as high-throughput sequencing, the decreasing cost of these 
technologies, and the maturation of infrastructure in related industries. This has lead 
to global collaborations and an unprecedented volume of openly accessible 
biomedical data. The European Bioinformatics institute for example, as of December 
2015, had provision to host a capacity of 75 petabytes of openly available biomedical 
data [97]. 
As a result of this growth, much of the data available via these biomedical data 
repositories are too large or complex to be easily processed, analysed or visualised 
using traditional methods. This category of data, often described as big data, 
presents a range of opportunities in the pharmaceutical industry, along with a 
number of challenges, and its use is already deeply ingrained in each step of the 
drug discovery pipeline. 
Big data is commonly defined based on a set of characteristics such as unusually 
large volume, velocity and / or variety. Succinctly put big data is ‘data that is too big, 
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too fast or too hard for existing tools to process’ [98]. However the changing nature 
of technology makes it hard to pinpoint exactly what constitutes big data using this 
definition and datasets that would have required supercomputers to manage a few 
years ago might now be easily processed on today's moderately powerful modern 
desktop. More generally datasets that require a mathematical model for their 
analysis rather than traditional direct analysis may fall into the category of big data 
[99]. 
 
5.1 Challenges of big data 
While big data presents many opportunities in drug discovery it also presents 
challenges, both technical and conceptual. Technical challenges such as storage 
capacity are non-trivial; it is predicted that by 2025, between 100 million and 2 billion 
human genomes could have been sequenced. This volume of data could require up 
to 40 exabytes of storage [100] and will require significant investment to manage 
[101,102]). The conceptual challenges of how we collect, analyse and treat the 
resulting insights gleaned from this data are key issues that must be addressed to 
ensure any work with big data is valid. These considerations are discussed below. 
As well as conventional concerns about data quality [103] ‘big data’ pose unique 
challenges as they are not, unlike traditional scientific data, representationally 
sampled and are widely collected without prior hypothesis. Data being harvested 
without a clear purpose from the outset can lead to unidentified systematic biases 
[104] or problems down-the-line as data collection is updated to use new, improved 
schematics resulting in disparate datasets [105]. At a deeper level, if we blindly rely 
on insight from data with no context or where underlying mechanisms are not well 
described, our results might easily be confounded in ways that are not detectable. 
 26 
Some practitioners are concerned that large volumes of data with no context may 
replace domain knowledge and scientific rigor, with the risk that the process of 
research in areas such as drug discovery moves from a scientific to an engineering 
discipline [106]. 
The mathematical model is key to the analysis of any large dataset and any collected 
data is only as useful as the model that represents it. Context in data (such as 
clinical annotation) can be hard to interpret at scale and is even harder to maintain 
when data are reduced to fit into a model [99]. Another concern when choosing a 
suitable model is how well the mechanism of your analysis can be interpreted. In 
traditional scientific processes each step of an experiment will be well understood 
and results should be easily interpreted to help both validate results and hopefully 
better understand underlying mechanics of the observed process. In mathematical 
models this isn’t always the case, a neural network for example embodies no model 
of decision or even a problem domain, it is effectively black box that provides 
predictions of future events based on unauditable processes [107] and should be 
used cautiously even as a complement to experimental validation. 
Even without mistakes at the collection or modelling stage, ‘big data’ analysis lends 
itself to number of statistical problems such as high false error rates [108] and 
overfitting [99]. Sound statistical practices, such as ensuring high-quality data, 
incorporating sound domain knowledge, and developing an overall strategy for 
modelling and validating problems, are even more crucial in big data analysis than it 
has been traditionally [109]. The importance of this statistical rigor is highlighted in 
well publicised cases such Potti et al. [70] where uncorrected sources of variation 
and inappropriate statistical methods led to cancelled clinic trials and a full retraction. 
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Many argue that big data should only ever be used as a complement to experimental 
validation and indeed there is currently much discussion within the Cancer Target 
Discovery and Development Network as to what level of experimental evidence is 
required to complement insights extracted from big data analysis [110]. 
 
5.2 Data standards 
Perhaps the result of being an emerging field many of the categories of biological 
data captured do not have a conventional set of standards and as such many study 
reports and even repositories provide data with disparate format and labelling 
schemes [111]. Although the problem is computationally tractable, a lack of coherent 
standards can result in some difficulties when attempting to integrate different data 
types. As the field matures and certain standards are adopted over others we expect 
to see a continued consolidation of these standards [112]. 
Although improved standards will be a welcome improvement, the pace at which 
‘omic’ techniques are progressing may still leave behind legacy data with redundant 
formats and incomparable datasets. To take just one example the ease and cost of 
generating gene expression data has been much improved with the advent of RNA 
sequencing. Yet even this single technique requires a number of choices to be made 
- from enrichment of mRNA in the laboratory to decisions about whether to map 
reads to the genome or to the annotated transcriptome [113]. Projects such as 
ICGCmed explicitly aim to enable comparability of results from experiments across 
the world and to build in some future proofing. Inevitably any static set of standards 
will be and should be overtaken by new innovations. In the author's view, the best 
that can be hoped for is a standards committee to agree, and promote best practice 
within the consortia; clear documentation showing the end user what analyses have 
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been carried out; a planned programme of revisions to standards; and finally a series 
of experiments carried out using both old and new standards in order to validate 
changes and throw light on the extent of comparability. 
Even with potentially improved standards data in biological data repositories are not 
always easy to access. The Genomic Data Commons (GDC), one of the richest 
sources of data on the molecular biology of cancer, is also one of the hardest to 
navigate. Any substantial download requires an ability to use the terminal and write 
short scripts and it is not always straightforward to associate the files with the 
samples from which they came. For the GDC to realise its aim as a foundation of 
future cancer research, enabling remote experiments via cloud-based technologies 
the GDC will need to ensure that documentation about experimental technologies, 
pre-processing pipelines, and database terms is comprehensive and easy to find, 
and that there is an improved focus on the user experience of downloading data and 
matching samples to data. Despite there being copious guidance on the website, 
there is very little to encourage the novice user. Providing online tutorials and 
workshops would be a good way to introduce new users to these resources. 
Although the raw data may be difficult to manipulate, many of the online tools (e.g. 
CBioPortal [38]) allow cancer researchers to easily manipulate and explore 
previously pre-processed data. 
Biological big data offers an unprecedentedly resource for cancer drug discovery but 
with this opportunity comes the risk of misapplication of the data. As the volume of 
data available for study increases so does the likelihood of false error or overfitting 
[108] unless we employ rigorous statistical fail-safes [114]. We must also ensure that 
any models used for analysis are appropriate for the dataset or risk losing important 
signal as the data is fitted to the model [99]. Even with best practice use of data in 
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place cancer biology is too complex to rely on data blindly and as such big data 
analyses should only ever be used as a complement to experimental validation 
[110]. 
Another notable weakness in contemporary genomic ‘big data’ is the sparsity of 
paired clinic data such as cancer diagnostic data [115], response to treatment 
regimes and patient lifestyle data. Fortunately, ICGCmed, the next phase of the 
ICGC project, aims to link current (and new) multi-platform data to clinical and health 
information [116] with discussion of making the inclusion of clinical data a 
requirement for data submission, this stipulation would certainly incentivise 
researchers to provide a previously relatively neglected data of great value to drug 
discovery research groups. This gives rise to ethical issues that are similar to those 
encountered in traditional medical genetics. The large amount of information that 
could be obtained by ‘Big Data’ approaches requires a careful evaluation on how to 
implement core ethical principles including: informed consent, privacy and data 
ownership and sharing, technology regulation, and the issues of access to the data 
[120]. In the case of the ICGC, concerns over ethical or privacy of the data are 
addressed through ICGCs stringent policies on restricted data access. 
 
6 Conclusions 
Continued advances in technology has enabled us to analyse increasingly large 
datasets and international initiatives to curate and collate this data provide an 
unprecedented resource for contemporary research communities. There are 
however still improvements to be made. Issues regarding collection, quality control, 
standardisation, access and statistical rigour that will need to be addressed before 
these methods and resources are fully matured. 
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Cancer chemotherapy is currently undergoing a step change, transitioning from 
traditional, general treatments such as potentially harmful cytotoxic agents to a much 
more selective approach including the use of targeted and even tailored therapies. 
This development is in large part a result of the growing availability of biological ‘big 
data’ across a wide range of platforms and tools developed to transform that data 
into actionable insight. 
The need for improved cancer therapies has led to a wide range of pan-cancer 
studies that integrate large volumes of data from many platforms. These studies 
have allowed us to build both our knowledge of the mechanics behind the cancers 
and the resulting weaknesses that can potentially be exploited as drug targets. 
Further studies have provided ways for us to predict the suitability of these drug 
targets potentially saving some of the significant time and cost that come as a result 
of failure in the drug discovery process. 
Although ‘big’ data cannot be used as any other than a complement to experimental 
validation it continues to prove a crucial part of modern drug discovery as we map 
out the landscapes of cancers and better characterise different cancer subtypes to 
ultimately provide a more effective, resilient and targeted set of cancer therapies. 
 
 
7 Expert opinion 
The national and international coordination of ‘big data’ multi-omic approaches to 
characterise tumours has produced an unparalleled opportunity for the cancer 
community to systematically identify all cancer drivers. The continued growth in 
volume and availability of genetic data presents many opportunities in the field of 
cancer drug discovery. These improvements will include identifying markers for early 
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detection of disease, more specific criteria and methods for diagnoses and 
prognoses, and interventions based on matching the patient’s disease molecular 
subtype with the most effective combinations of therapies. However improvements 
are required in both in capturing and storing the data and in its ability to be accessed 
and analysed by informaticians and cancer researchers alike. 
Next generation sequencing and other ‘omic’ technologies are enabling better 
stratification of a wide range of cancers, which will eventually lead to targeted 
therapies and personalised medicines. The best known example of patient 
stratification is the analysis of biomarkers for patients with breast cancer that are 
used to determine treatment regimes. Tests and endocrine therapies already exist 
for patients testing positive for elevated levels of HER2, estrogen or progesterone 
and these complement chemotherapy, radiation therapy and surgery, the current 
standard-of-care in cancer treatment. One of the most pressing needs in cancer 
bioinformatics is to provide this type of characterisation for other cancers, identifying 
stable patient cohorts with similar therapeutic needs and potential outcomes and 
reducing the use of aggressive therapies where they are not warranted. 
Such approaches offer the possibilities of developing biomarkers to improve existing 
therapies, providing information for potential drug design, or simply improve the 
accuracy of prognoses and have been used to stratify a number of cancers including 
breast cancers, ovarian cancer [117,118] and Acute Myeloid Leukaemia [119]. 
Predicting and overcoming resistance is also a major challenge for targeted cancer 
therapies as it was for the earlier chemotherapies. Some of the more recent targeted 
therapies have provided at best only short-lived remissions before resistance takes 
hold. This is due either to the prior existence of resistant sub-clones or continued 
evolution of the tumour under the selective pressure of a drug regime [8,9]. The goal 
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of using a tailored approach to treat all tumour patients may therefore require 
combination therapies with one or more drugs to prevent resistance developing. 
‘Big data” can also facilitate the success of clinical trials. Testing novel compounds 
against characterised cell-line collections may help enable preclinical stratification to 
identify sensitive cancers. Data produced from these types of study can be used to 
inform clinical trial design and aid the development of personalised therapeutic 
regimens 
The continued growth in volume and availability of ‘big data’ presents many 
opportunities in the field of cancer drug discovery and offers promising ways to 
inform decisions at each step of the discovery pipeline from drug target identification 
and corresponding molecule selection to stratifying patients allowing for better 
targeted trials and reduced attrition rates. Using large-scale integrated data, 
researchers, scientists, policymakers and clinicians will be able to work with patients 
and healthcare providers to deliver truly personalised cancer care. 
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Article Highlight Box 
! Large-scale studies of genetic mutations have identified at best a  very small 
number of highly recurrent altered genes, with increasingly long tails of much 
more infrequently altered genes. Studies that cluster these rarer mutations are 
providing insight  into biological understanding of the pathways involved in 
cancers. 
! The patterns of mutations within driver genes enable identification  of genes 
into oncogenes and tumour suppressors. Tumour suppressors cannot often 
be directly targeted. Instead analysis is required to find gene products that are 
synthetically lethal to the tumour suppressor and can be inhibited 
pharmacologically. The DNA damage response pathways are particularly 
fruitful sources of tumour  suppressors that can be targeted in this way. 
! The genetic dependencies of cancer cell lines can be profiled, identifying 
where the cancer has become addicted to support from altered pathways, 
allowing new therapeutic options. Analysis of omic data from cell lines tested 
with novel compounds has allowed genetic, lineage, and gene-expression-
based predictors of drug sensitivity. 
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! Proteins can be assessed for druggability by modelling 3D structure and 
analysing the extent to which ‘pockets’ in the protein bind pharmacologically 
suitable molecules with high affinity and specificity. Where proteins are not 
suitable analysis is needed to find synthetic dosage lethal partners. 
! Much of the data produced from these large-scale studies is publicly 
available, together with tools allowing integrated analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
